Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees will meet jointly Oct. 20 to consider AstraZeneca's NDA 21-229 to switch its blockbuster drug Prilosec (omeprazole) OTC; the nonprescription product would be distributed by Procter & Gamble. Proposed indications the committees will review are: "To relieve heartburn, acid indigestion and sour stomach" and "To prevent heartburn, acid indigestion and sour stomach brought on by consuming foods and beverages or associated with events such as stress, hectic lifestyle, lying down or exercise." On Oct. 19, NDAC will consider the safety of phenylpropanolamine, giving attention to a CHPA-sponsored Yale study on the risk of hemorrhagic stroke and PPA (1"The Tan Sheet" May 29, p. 11)


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts